Abridge Wants Operating System for Medicine Backed by NVIDIA
Abridge secures NVIDIA and Eli Lilly support to push an ambient AI platform toward a full hospital operating system. ...
Eli Lilly
Discover Eli Lilly stock insights from 4 articles covering long-term bets, timing questions, bullishness priced in, and FDA news. Learn what matters and refine portfolio today.
53 articles
Lilly Novo Nordisk Battle Intensifies as Obesity Drugs Surge
Eli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
Prediction: Lilly Will Trade at Record High in 12 Months
Eli Lilly stock is surging on fresh obesity-drug data, fueling bets that the name could push toward a record high wit...
Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
Prediction: Lilly Will Reach $1,200 in 2026 — Investment Thesis
Eli Lilly’s GLP-1 drugs are redefining growth in obesity and diabetes treatment. This article lays out why the stock ...
Health Just Announced Fantastic News for Lilly Investors
A major payer shift could unlock stronger demand for Eli Lilly’s obesity and GLP-1 products. This in-depth analysis e...
Reasons Lilly Remains a Buy: 3 Strong Drivers for Investors
Investors are eyeing Lilly for its resilient growth, strong pipeline, and shareholder-friendly strategy. This piece b...
Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
These Words From Lilly's CEO Signal Bullish Wall Street
A single conference-call moment changed the mood around Eli Lilly. By unpacking eight key themes from the CEO, invest...
Stock Split Watch: Lilly — Is Eli Lilly Next to Split?
Eli Lilly has been a standout growth stock thanks to GLP-1 drug demand. Could a stock split be on the horizon? This g...
Novo Nordisk Beating Lilly in Obesity Pill Market: What It Means for Investors
Novo Nordisk is gaining ground on Lilly in the obesity pill market. This article breaks down the drivers, the competi...
Lilly Just Made Game-Changing Moves in Weight-Loss Space
A big strategic shift from Lilly could redefine how investors view weight-loss drugs. This article breaks down what h...